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Atherogenic lipoproteins and tyrosine kinase mitogenic signal- number in the early phases of many glomerular diseases
ing in mesangial cells. characterized by progressive glomerulosclerosis [1]. Hu-
Background. Mesangial hypercellularity is a critical early man and experimental glomerular diseases that appearhistopathological finding seen in human and experimental glo-
to support these sequence of events, namely increasedmerular diseases. Hyperlipidemia and the glomerular deposi-
mesangial cell number followed by glomerulosclerosis,tion of atherogenic lipoproteins [for example, low-density lipo-
protein (LDL) and its oxidized variants, minimally oxidized/ include diabetic nephropathy, IgA nephropathy, mem-
modified LDL (mm-LDL)] are commonly associated with mes- branoproliferative glomerulonephritis, and experimen-
angial hypercellularity and the development of glomerular dis- tal models of anti-Thy-1–induced mesangial proliferativeease. This article reviews signal transduction pathways involved
nephritis, puromycin aminonucleoside-induced nephro-in cell proliferation and provides evidence for the participation
of atherogenic lipoproteins in intracellular signaling pathways sis, and remnant kidney glomerular hypertension [1, 2].
for mesangial cell proliferation. The mitogenic intracellular The current understanding favors the premise that the
signaling pathways are regulated by the activation of a series increased mesangial cells in the early phases of glomerular
of transmembrane and cytoplasmic protein tyrosine kinases
disease may influence the synthesis and deposition of ex-that converge into the activation of Ras and downstream mito-
tracellular matrix (ECM) proteins, leading eventually togen-activated protein (MAP) kinase. Activated MAP kinase,
through translocating into the nucleus and the activation of sclerosis and renal failure. Indeed, such an association
various transcription factors and proto-oncogenes, regulates and/or link between proliferation of mesangial cells and
cellular proliferation. subsequent ECM deposition has been observed in severalMethods. Murine mesangial cells were stimulated with LDL
experimental glomerulonephritis models, and the admin-and mm-LDL and were analyzed for the tyrosine kinase activ-
istration of platelet-derived growth factor (PDGF), aity, phosphorylation of membrane proteins, activation of Ras
and MAP kinase, and cell proliferation. known mitogen, to experimental animals stimulated both
Results. The results indicated that the stimulation of mesan- mesangial cell proliferation and subsequent ECM expan-
gial cells with LDL and, with greater activity, mm-LDL induced sion [1, 2]. Experimental maneuvers that decrease glo-the phosphorylation of membrane platelet-derived growth fac-
merular cellular proliferation in control or anti-Thy-1–tor (PDGF) and epidermal growth factor (EGF) receptors,
induced glomerulonephritis rats have also resulted in aactivated Ras, and resulted in sustained (up to 24 hr) activation
of MAP kinase. LDL/mm-LDL–mediated mesangial cell pro- relative decrease in ECM [reviewed in 2]. Taken to-
liferation and MAP kinase activation were dependent on the gether, these studies support the hypothesis that dysregu-
activation of tyrosine kinases.
lated glomerular mesangial cell mitogenesis may serveConclusions. We suggest that the accumulation of LDL and
as one of the major pathobiological prerequisite factorsmore potently its oxidized forms within the glomerulus, through
the activation of membrane receptor tyrosine kinases, activate for the early development and/or all phases of progres-
the Ras and MAP kinase signaling cascade leading to DNA sive glomerular disease.
synthesis and subsequent cell proliferation. Although the precise cellular and molecular mecha-
nisms associated with mesangial hypercellularity in di-
verse glomerular diseases are not clearly defined, the
Previous studies aimed at understanding the physiol- stimuli for mesangial cell proliferation in response to
ogy and pathophysiology of the glomerulus have revealed glomerular injury have been attributed to multiple fac-
an apparent increase in intraglomerular mesangial cell tors, including growth factors, inflammatory mediators,
immune complexes, and complement components [re-
viewed in 1–3]. These factors involved in mesangial hy-Key words: glomerular disease, low-density lipoprotein, mesangial
hypercellularity. percellularity may be derived from intrinsic glomerular
cells, acting in an autocrine or short-term paracrine man- 1999 by the International Society of Nephrology
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ner, or from infiltrating inflammatory cells. In addition SIGNAL TRANSDUCTION PATHWAYS FOR
CELL PROLIFERATIONto these endogenous mediators, metabolic abnormalities
or putative products generated by the metabolic de- The intracellular signaling pathways involved in cell
rangement have also been suggested in the pathogenesis proliferation generally proceed in an orderly fashion by
of glomerular disease. In this regard, a growing body of generating early multiple intracellular protein phosphor-
evidence indicates that abnormalities in lipid and athero- ylation signals in the membrane and cytosol, and within
genic lipoprotein metabolism play an important pathobi- minutes, the mitogenic signal is propagated into the nu-
ological role in the development of glomerular disease cleus for DNA synthesis and cell multiplication. As noted
[reviewed in 4, 5]. In this article, we review recent devel- in a simplified established model of mitogenic signal
opments in lipid-mediated pathobiological events of glo- transduction paradigm (Fig. 1), cellular mitogenic stimu-
merular injury (with special emphasis on mesangial cell lus (for example, growth factors, serum, or possibly other
proliferation) and provide evidence to suggest that ath- endogenous mitogenic metabolic products) can lead to
erogenic lipoproteins, by modulating protein tyrosine the autophosphorylation and activation of intrinsic tyro-
kinase (PTK)-Ras–mediated signaling events, regulate sine kinase activity of specific membrane receptors, which,
mesangial cell proliferation. in turn, serves as high-affinity binding sites for the Src
homology 2 (SH2) domain sequences that are encoded
in different proteins [reviewed in 14]. Src homologousROLE OF CHOLESTEROL AND
and collagen (Shc) and growth factor receptor-boundATHEROGENIC LIPOPROTEINS IN
protein 2 (Grb2) adaptor proteins, containing SH2 do-MESANGIAL CELL PROLIFERATION,
mains, through phosphorylation by membrane receptors,EXTRACELLULAR MATRIX DEPOSITION,
interact with son of sevenless, an exchange catalyst thatAND THE DEVELOPMENT OF
stimulates GDP dissociation from Ras, allowing the GTPGLOMERULAR INJURY
binding and activation of Ras. The activated Ras associ-
A causal relationship between hyperlipidemia and glo-
ates with the N-terminal regulatory domain of Raf pro-
merular disease has long been recognized in hyperlipid-
tein kinases, leading to the activation of Raf kinase. Raf
emic experimental models [reviewed in 4, 5]. Further-
has been shown to be an integrator of signals received
more, recent studies from our and other laboratories from various pathways, including receptor tyrosine ki-
have demonstrated multiple abnormalities in hepatic nase and upstream serine-threonine kinases such as pro-
cholesterol and low-density lipoprotein (LDL) metabo- tein kinase C (PKC), and through activating MAP kinase
lism in human and experimental models of nephrosis and kinase (MEK) stimulates mitogen-activated protein
chronic renal failure and provided cellular and molecular (MAP) kinase cascade. The activated cytoplasmic MAP
mechanisms by which atherogenic lipoproteins facilitate kinase has been thought to translocate into the nucleus
cytokine-mediated monocyte infiltration into the glo- and activate various transcription factors and proto-
merulus (abstract; Ha et al, J Am Soc Nephrol 6:830A, oncogenes associated with cell growth and proliferation.
1995) [4–8]. In addition to the increased systemic concen- Additionally, multiple signaling cascade including PKC,
trations of atherogenic lipoproteins (for example, LDL), PTK, and G-protein–coupled receptors may interact to
recent studies have indicated a pathological accumula- activate Ras-MAP kinase cascade (Fig. 1). In late G1,
tion of lipids, LDL, and oxidized variants of LDL within the mitogenic signals discussed earlier here converge
the glomerulus of diverse human and experimental renal with cyclin/cyclin-dependent protein kinases that regu-
diseases [9, 10]. Increased mesangial deposition of apoli- late subsequent cell multiplication.
poprotein (apo) B and/or E (major proteins of LDL)
seen in patients with primary and secondary glomerular
ROLE OF LIPIDS AND LIPOPROTEINS INdisease was associated with mesangial hypercellularity,
INTRACELLULAR SIGNALINGincreased urinary protein excretion, and the develop-
ment of glomerulosclerosis [11]. Because mesangial hy- The role of lipids and atherogenic lipoproteins in intra-
percellularity and ECM deposition are common histo- cellular signaling events for various cellular responses in
logical abnormalities (in addition to enhanced monocyte glomerular mesangial cells is not known. However, in non-
infiltration) in hyperlipidemia-induced experimental glo- glomerular cells, the major signal transduction events as-
merular disease [reviewed in 4, 5], it has been thought sociated with LDL, oxidized LDL (ox-LDL), or lysophos-
that alterations in lipids and lipoproteins may have detri- phatidylcholine (LPC, a major component of ox-LDL)
mental effects on mesangial cell proliferation and associ- have been attributed to the stimulation of phosphoinosi-
ated events. In support of this premise, recent studies tide hydrolysis and activation of PKC [15]. Cholesterol
using cultured mesangial cells provided direct evidence enrichment of smooth muscle cells or interaction of ox-
for the mitogenic effects of LDL on mesangial cell prolif- LDL with aortic endothelial cells is shown to inhibit
the expression of Gi proteins, and the attenuation oferation [12, 13].
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Fig. 1. Signal transduction paradigm for cell proliferation. Cellular mitogenic stimulus can induce the autophosphorylation and activation of
intrinsic tyrosine kinase activity of specific membrane receptors, which, in turn, can sequentially activate Ras, Raf, and MAP kinase. The
activated cytoplasmic MAP kinase translocates into the nucleus and activates various transcription factors and proto-oncogenes associated with
cell proliferation. PKC and G-protein–mediated events can also activate MAP kinase signaling. Atherogenic lipoproteins, by activating specific
membrane receptors, may induce the activation of Ras-MAP kinase signaling.
endothelial-derived relaxation by LDL or LPC were as- STUDIES ON THE EFFECT OF ATHEROGENIC
LIPOPROTEINS ON PROTEIN TYROSINEsociated with Gi-protein–mediated pathways [16, 17]. Al-
KINASE-MEDIATED INTRACELLULARthough the effect of cholesterol enrichment on cell prolif-
SIGNALING IN MESANGIAL CELLSeration is not clearly known, the inhibition of cholesterol
synthetic pathway by HMG-CoA reductase inhibitors Using murine mesangial cells (stably transformed with
(for example, lovastatin) has been shown to inhibit cell SV-40; American Type Culture Collection, Rockville,
proliferation in various cell types, including mesangial MD, USA) as an in vitro model system, the following
cells [18]. The mechanism of action of HMG-CoA reduc- subsections describe the summary of our studies that
tase inhibitors on cell proliferation has been attributed examined the effect of LDL, minimally modified/oxi-
to the inhibition of farnesol synthesis and associated dized LDL (mm-LDL, a proposed potent oxidized form
isoprenylation of Ras proteins, important signaling mole- of LDL within the vascular or glomerular tissue), and
cules involved in cell proliferation [18]. Additionally, a LPC on specific PTKs, Ras, and MAP kinase signaling
growing number of studies have emerged to demonstrate pathways, and the involvement of PTKs in mesangial
the participation of other potent lipids (for example, cell proliferation (abstract; Kamanna et al, J Am Soc
phosphatidic acid, lysophosphatidic acid, glycerolipids, Nephrol 8:2042, 1997) [20, 21].
sphingolipids, and arachidonic acid/its metabolites) in
Role of atherogenic lipoproteins in mesangial cellPKC, G protein, and/or mitogenic signaling [reviewed
proliferation: Involvement of protein tyrosinein 19]. As summarized later here, we have shown that
kinase-dependent mechanismsLDL and its oxidized variants can activate specific tyro-
sine kinase-MAP kinase signaling cascade involved in Incubation of quiescent mesangial cells with either
LDL or mm-LDL for 24 hours dose-dependently (2.5 tomesangial cell proliferation.
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Table 1. Summary of mesangial cell intracellular mitogenic signaling events modulated by atherogenic lipoproteins
Alterations in intracellular mitogenic processes LDL mm-LDL LPC
(compared to controls) 2.5–25 lg/ml 2.5–25 lg/ml 5–25 lm
Elevation of membrane PTK activity 12–20% 30–40% 15–25%
Increased cellular tyrosine phosphorylation profile
(molecular wt: 150–200 kD) 1.5–2-fold 3–4-fold ND
Phosphorylation of receptors for EGF and PDGF 1.5–2.5-fold 2–4-fold ND
Activation of Ras 1.2–1.5-fold 3–5-fold 3–6-fold
Activation of MAP kinase 1.3–1.6-fold 1.9–2.6-fold 1.75–3-fold
Increase in DNA synthesis 1.4–1.6-fold 2.1–2.8-fold ND
ND is not determined.
20 mg/ml) induced the incorporation of 3H-thymidine, as example, PDGF receptor, EGF receptor). The data indi-
an index of increased DNA synthesis and cell prolifera- cated that LDL and mm-LDL (10 mg/ml) induced the
tion (abstract; Kamanna et al, J Am Soc Nephrol 8:2042, phosphorylation of PDGF and EGF receptors (as early
1997) [20]. The effect of mm-LDL was 2.1- to 2.8-fold as 5 to 60 min, as measured by in vivo 32Pi-labeling: sodium
greater when compared with controls (Table 1). To un- dodecyl sulfate-polyacrylamide gel electrophoresis of
derstand the possible involvement of PTKs in LDL/mm- PDGF/EGF receptor-immunoprecipitates, and autoradi-
LDL–mediated cell proliferation, additional DNA syn- ography; abstract; Kamanna et al, J Am Soc Nephrol
thesis studies were done using specific PTK inhibitors 8:2042, 1997). Because LDL/mm-LDL–induced signal-
(for example, genistein and herbimycin). Preincubation ing occurred within 3 to 15 minutes of stimulation, it is
of mesangial cells with either genistein (25 mg/ml) or very unlikely that the effect of LDLs could be due to
herbimycin (10 mm) for two hours blocked LDL/mm- growth factors secreted into the media. In fact, stimula-
LDL (10 mg/ml)–induced mesangial cell proliferation, tion of mesangial cells with LDLs for 10 to 30 minutes
suggesting the involvement of PTK-mediated signaling
had no significant effect on growth factor secretion.
mechanisms (Table 1). Additional studies indicated that
both LDL and mm-LDL (10 mg/ml) increased cell mem- Effect of LDL/mm-LDL on Ras and mitogen-
brane PTK activity (as determined by an assay kit using a
activated protein kinase activation: participationsynthetic peptide of 12 amino acids surrounding tyrosine
of protein tyrosine kinase or Gi-proteinsphosphorylation site in pp60src, specific for epidermal
As LDL/mm-LDL activated the upstream membranegrowth factor (EGF) receptor; Life Technologies, GIBCO
receptor phosphorylation, additional studies were per-BRL products, Grand Island, NY, USA) by 14 and 36%,
formed to examine the impact on downstream Ras (mea-respectively (Table 1; abstract; Kamanna et al, J Am Soc
Nephrol 8:2042, 1997). sured by association of GTP with immunoprecipitated
p21Ras) and MAP kinase (assessed by immunoprecipita-
Effect of LDL/mm-LDL on cellular protein tion and kinase assay using myelin basic protein as a
phosphorylation profile and identification of substrate) signaling. Both LDL and mm-LDL (5 to 25
specific phosphorylated membrane proteins
mg/ml) stimulated MAP kinase activity (10 to 30 min
Because PTK-mediated mitogenic signaling occurs and persisted up to 24 hr) [20], and the effect of mm-LDL
through phosphorylation of upstream membrane and/or was much higher than LDL (Table 1). PTK inhibitors
cytoplasmic proteins (Fig. 1), we examined the effect (genistein and herbimycin) blocked LDL/mm-LDL–
of LDL/mm-LDL on the possible phosphorylation of induced MAP kinase activity. Pretreatment of cells with
cellular/membrane proteins. Preliminary studies indi- pertussis toxin (which inactivates Gi-proteins) had nocated that the stimulation of mesangial cells with LDL
effect on LDL-induced MAP kinase activation, indicat-
and mm-LDL (5 to 25 mg/ml), as early as five minutes,
ing that Gi proteins may not be involved in LDL-medi-markedly induced the phosphorylation of cellular pro-
ated MAP kinase activation. The incubation of mesan-teins of higher molecular weight proteins (150 to 200
gial cells with mm-LDL (10 mg/ml) as early as 3 minuteskDa) and some modest phosphorylation of lower molec-
and up to 10 minutes markedly stimulated the activationular weight proteins (40 to 60 kDa; Table 1, as assessed
of Ras, and LDL had marginal stimulatory effects onby Western blot: 7.5% sodium dodecyl sulfate-polyacryl-
Ras activation by 10 minutes of incubation (Table 1;amide gel electrophoresis, immunoblotting with anti-
abstract; Kamann et al, J Am Soc Nephrol 8:2042, 1997)phosphotyrosine). mm-LDL had a twofold to threefold
[22]. Because high-density lipoprotein (HDL, anothergreater effect. We reasoned that the higher molecular
major lipoprotein) had no effect on MAP kinase, theweight phosphorylated proteins in the range of 150 to
200 kDa may be one or more membrane receptors (for mitogenic effects appear to be specific for LDL.
Kamanna et al: Atherogenic lipoproteins and mitogenic signalingS-74
Effect of lysophosphatidylcholine on cascade associated with cell DNA synthesis and subse-
quent cell proliferation (Fig. 1).mitogenic signaling
Lysophosphatidylcholine, one of the major compo-
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